Madrigal Pharmaceuticals EASL 2022 Resmetirom Investor Event

Madrigal Pharmaceuticals presents EASL investor event data on resmetirom (MGL-3196), an investigational therapy for non-alcoholic steatohepatitis (NASH). The presentation covers clinical trial results, development objectives, and potential efficacy for treating NASH and liver fibrosis.